US 8193197
Compositions and methods for inhibition of the JAK pathway
granted A61KA61K31/505A61K31/506
Quick answer
US patent 8193197 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Jun 05 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 38
- CPC classes
- A61K, A61K31/505, A61K31/506, A61K31/5377, A61K31/5383